Elanco Animal Health posts 10% Q2 revenue growth, raises FY26 guidance

Revenue rose 10% YoY to $1.368 billion with 8% organic constant currency growth. Adjusted EBITDA increased 21% YoY to $288 million; gross margin expanded 80 bps. U.S. Pet Health and U.S. Farm Animal segments both grew 11% organically. Full-year adjusted EPS guidance raised to $1.10-$1.16, implying 20% growth at midpoint. Net leverage reduced to 3.1x; year-end target lowered to approximately 3x.

Elanco CEO Jeff Simmons to speak at BofA Healthcare Conference

Elanco CEO Jeff Simmons to speak at BofA Securities Global Healthcare Conference. Fireside chat scheduled for September 22, 2026, at 2:10 p.m. BST. Live audio webcast available on Elanco investor website.

Elanco completes $120m Elwood mAb expansion to scale biologics

Elanco completed a $120 million, 25,000-sq ft mAb expansion at its Kansas site. Capacity increases by more than four times to support Befrena and Trutect production. Befrena demand is two times above expectations; unconstrained supply expected early 2027. Total investment will reach $150 million with additional $30 million for warehousing by 2028.

Elanco secures FDA EUA for CLiK Extra to combat New World screwworm

Elanco Animal Health has obtained FDA Emergency Use Authorization for CLiK Extra to prevent New World screwworm infestations in livestock and wildlife, responding to the parasite's return to the U.S. The spray applies to wounds in cattle, sheep, goats, swine, and specific wildlife, with an 86-day slaughter withdrawal period for most species. This addition complements existing emergency approvals for Negasunt Powder and Tanidil, offering producers enhanced preventive options while strict safety and usage protocols remain in place.

Elanco Q2 Results: Revenue rises 10%, guidance raised

Elanco Animal Health beat Q2 2026 earnings estimates with $0.34 per share vs $0.27 consensus. Revenue grew 10% YoY to $1.368 billion, led by Pet Health. The company raised FY26 earnings guidance to $1.10-$1.16 and sales to $5.09-$5.14 billion, citing strong product momentum and margin expansion.

Elanco reports $892 million in 2025 innovation revenue

Elanco Animal Health released its 2025 Impact Report, reporting $892 million in innovation revenue and a pipeline with over $2 billion in potential peak sales. The company also highlighted environmental achievements, including more than 200,000 metric tons of CO₂e reductions, and strong employee engagement metrics.